Summary & Overview

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

DRG 125 groups inpatient stays for other disorders of the eye without Major Complication or Comorbidity, encompassing non-severe ocular diagnoses and procedures that do not qualify for higher-severity payment. It matters for inpatient reimbursement because correct DRG assignment determines the bundled Medicare payment and influences hospital case-mix and revenue.

Other Disorders of the Eye without MCCDRG Other Disorders of the Eye without MCCDRG 125Diagnosis-Related GroupInpatient ReimbursementMedicareOphthalmologyEye SurgeryOphthalmic Procedures

DRG 125 Overview

DRG 125 covers inpatient cases for other disorders of the eye without Major Complication or Comorbidity. This group includes a range of non-severe ocular conditions and procedures that do not meet criteria for higher-severity classification. It matters for Medicare payment because it defines the bundled reimbursement for hospital stays where eye conditions are primary, influencing resource coding and payment level. Accurate assignment affects hospital Medicare revenue and case-mix reporting.

Clinical Trials

Acute procedural and perioperative safety studies investigating minimally invasive surgical techniques and anesthesia approaches for non-complex ocular conditions (for example, minor lid surgeries, non-penetrating glaucoma procedures, or retinal laser interventions). These studies enroll hospitalized patients who require short inpatient stays for eye procedures without major comorbid complications, and they collect intraoperative and immediate postoperative outcomes such as pain, bleeding, infection rates, and short-term visual function. Findings are relevant to providers and payers because they inform short-stay care pathways, resource use during the index admission, and risk stratification that can reduce length of stay and avoid escalation to higher-cost DRGs.
Comparative effectiveness trials evaluating different medical management strategies for acute but non-MCC eye disorders, such as randomized or pragmatic trials comparing topical regimens, anti-inflammatory protocols, or outpatient versus brief inpatient antibiotic strategies for infectious or inflammatory eye conditions. These trials focus on adults admitted for eye conditions that do not meet MCC criteria but require inpatient monitoring (e.g., severe conjunctivitis, uveitis flares, or corrosive injuries limited to ocular surfaces), assessing resolution time, readmission, adverse events, and functional vision outcomes. Results guide clinicians and payers on which conservative inpatient treatments provide the best balance of clinical benefit, safety, and cost, helping to define standardized inpatient care bundles and reduce unnecessary escalation of care.
Post-discharge outcomes and utilization studies that follow patients discharged under this DRG to measure 30- to 90-day functional vision recovery, outpatient follow-up adherence, rates of readmission or ED visits for ocular issues, and patient-reported vision-related quality of life. These observational cohorts or registry-based studies include diverse inpatient populations (older adults, patients with baseline ocular comorbidity) to identify predictors of poor recovery and gaps in care transitions such as missed ophthalmology follow-up or lack of rehabilitation services. This research is important for payers and hospitals to target transitional care interventions, allocate post-discharge resources, and reduce downstream utilization and costs associated with unresolved or recurring eye problems.

Clinical Trials

Acute procedural and perioperative safety studies investigating minimally invasive surgical techniques and anesthesia approaches for non-complex ocular conditions (for example, minor lid surgeries, non-penetrating glaucoma procedures, or retinal laser interventions). These studies enroll hospitalized patients who require short inpatient stays for eye procedures without major comorbid complications, and they collect intraoperative and immediate postoperative outcomes such as pain, bleeding, infection rates, and short-term visual function. Findings are relevant to providers and payers because they inform short-stay care pathways, resource use during the index admission, and risk stratification that can reduce length of stay and avoid escalation to higher-cost DRGs.
Comparative effectiveness trials evaluating different medical management strategies for acute but non-MCC eye disorders, such as randomized or pragmatic trials comparing topical regimens, anti-inflammatory protocols, or outpatient versus brief inpatient antibiotic strategies for infectious or inflammatory eye conditions. These trials focus on adults admitted for eye conditions that do not meet MCC criteria but require inpatient monitoring (e.g., severe conjunctivitis, uveitis flares, or corrosive injuries limited to ocular surfaces), assessing resolution time, readmission, adverse events, and functional vision outcomes. Results guide clinicians and payers on which conservative inpatient treatments provide the best balance of clinical benefit, safety, and cost, helping to define standardized inpatient care bundles and reduce unnecessary escalation of care.
Post-discharge outcomes and utilization studies that follow patients discharged under this DRG to measure 30- to 90-day functional vision recovery, outpatient follow-up adherence, rates of readmission or ED visits for ocular issues, and patient-reported vision-related quality of life. These observational cohorts or registry-based studies include diverse inpatient populations (older adults, patients with baseline ocular comorbidity) to identify predictors of poor recovery and gaps in care transitions such as missed ophthalmology follow-up or lack of rehabilitation services. This research is important for payers and hospitals to target transitional care interventions, allocate post-discharge resources, and reduce downstream utilization and costs associated with unresolved or recurring eye problems.

OpenPayer

Summary & Overview

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

DRG 125 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes